Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L ... triple-negative breast cancer patients who exhausted ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Background: TRIB3 has been reported to mediate breast cancer (BC) proliferation and metastasis ... to study the potential mechanism of Parishin B (PB) anti-BC. Finally, the effect of TRIB3 inhibitor ...

HER2-positive breast cancer accounts for 20–30% of all breast ... ADCC, antibody-dependent cellular cytotoxicity; Akt, protein kinase B; c-Cbl, Casitas B-lineage lymphoma; CDK2, cyclin-dependent ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Two studies by researchers at the University of Konstanz investigated ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct ...

Study on cyclin B3: Rebecca Schunk, Marc Halder, Michael Schäfer, Elijah Johannes, Andreas Heim, Andreas Boland, Thomas U. Mayer: A phosphate-binding pocket in cyclin B3 is essential for XErp1 ...

No pocket = no correct cell division The research team led by Thomas Mayer has now demonstrated this mechanism for two cyclins from the B group. Cyclin B1 is relevant in mitosis, a type of cell ...

MAMMOTH and DENALI studies and shared details on future clinical development and potential registration plans for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Results from ...